NEULANDLAB - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 2.9
| Stock Code | NEULANDLAB | Market Cap | 15,532 Cr. | Current Price | 12,101 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 87.1 | Book Value | 1,257 ₹ | Dividend Yield | 0.10 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 13,370 ₹ | DMA 200 | 13,988 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.17 % | PAT Qtr | 40.4 Cr. | PAT Prev Qtr | 96.5 Cr. |
| RSI | 38.4 | MACD | -332 | Volume | 25,549 | Avg Vol 1Wk | 34,668 |
| Low price | 10,060 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.84 | Debt to equity | 0.16 |
| 52w Index | 21.1 % | Qtr Profit Var | -29.2 % | EPS | 139 ₹ | Industry PE | 27.2 |
Analysis: NEULANDLAB trades at 12,101 ₹, below both its 50 DMA (13,370 ₹) and 200 DMA (13,988 ₹), reflecting bearish momentum. RSI at 38.4 suggests the stock is nearing oversold territory, while MACD (-332) confirms strong negative sentiment. The P/E of 87.1 is far higher than the industry average (27.2), indicating overvaluation. Fundamentals are mixed: ROCE (18.7%) and ROE (14.8%) are decent, but quarterly PAT declined sharply (40.4 Cr. vs 96.5 Cr.), weakening short-term prospects. Overall, NEULANDLAB is a weak swing trade candidate at present, with valuation risks and bearish technicals outweighing positives.
Optimal Entry Price: Around 11,800–12,000 ₹, closer to support levels and near oversold RSI zone.
Exit Strategy (if already holding): Consider exiting near 13,300–13,500 ₹ (DMA resistance zone). Place a stop-loss around 11,600 ₹ to limit downside risk.
✅ Positive
- ROCE (18.7%) and ROE (14.8%) show moderate efficiency.
- EPS of 139 ₹ reflects strong earnings power.
- Debt-to-equity ratio of 0.16 indicates manageable leverage.
- FII holdings increased (+0.30%) and DII holdings increased (+1.17%), showing investor interest.
⚠️ Limitation
- High P/E (87.1 vs industry 27.2) signals overvaluation.
- Dividend yield is very low (0.10%), limiting income appeal.
- Stock trades below both 50 DMA and 200 DMA, showing bearish trend.
📉 Company Negative News
- Quarterly PAT declined sharply (96.5 Cr. to 40.4 Cr.).
- Weak technical indicators (RSI low, MACD strongly negative).
📈 Company Positive News
- Institutional interest increased (FII +0.30%, DII +1.17%).
- EPS remains strong despite profit decline.
🏭 Industry
- Industry P/E is 27.2, making NEULANDLAB relatively expensive.
- Pharmaceutical sector benefits from long-term demand but faces regulatory and margin pressures.
🔎 Conclusion
NEULANDLAB shows moderate fundamentals but weak technicals and high valuation, making it a poor swing trade candidate currently. Entry near 11,800–12,000 ₹ is safer, with exit around 13,300–13,500 ₹ if holding. Stop-loss at 11,600 ₹ is recommended. While institutional interest provides some support, declining profits and bearish momentum limit short-term upside potential.